Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
OMI 0.315 +0.0% BMM 3.80 +0.0% CGD 0.630 +10.5% OCG 0.275 −1.8% CAMB 0.990 −1.0% HMR 0.610 −1.6% GOFL 0.025 +0.0% SIG 1.01 −1.9% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.400 +0.0% LIB 0.800 −12.1% SMY 0.290 +23.4% SAG 1.02 +0.0% OMI 0.315 +0.0% BMM 3.80 +0.0% CGD 0.630 +10.5% OCG 0.275 −1.8% CAMB 0.990 −1.0% HMR 0.610 −1.6% GOFL 0.025 +0.0% SIG 1.01 −1.9% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.400 +0.0% LIB 0.800 −12.1% SMY 0.290 +23.4% SAG 1.02 +0.0%
M&A / Property Routine −

Aequus Announces Completion of Previously Announced Sale of ZIMED(R) PF

Aequus Offloads Final Asset for Half-Million as NEX Transfer Signals Corporate Wind-Down

By The Northwire Desk — AI Analysis Mar 31, 2026 · 12:40 AQS · 0.005 Aequus Pharmaceuticals Inc.
Executive Summary
  • The March 31, 2026 release confirms the completion of the previously announced sale of the ZIMED PF product to Luvo Medical Technologies Ltd. for approximately $531,693.
  • The original purchase agreement was amended to replace a 6% ongoing royalty with a one-time lump-sum royalty payment of $131,693, increasing total proceeds from the initially anticipated ~$400,000.
  • The company's TSX Venture Exchange listing will be transferred to the NEX board effective around April 3, 2026.
  • Historical context from the November 12, 2025 disclosure reveals ongoing corporate governance and regulatory friction, including a cease-trade order against director nominee Marc Lustig and conditional language surrounding a proposed share consolidation.
  • The progression from regulatory scrutiny and conditional restructuring to asset divestiture and exchange demotion indicates a clear corporate wind-down trajectory.
Material Impact
  • The transaction is a completion of a previously announced deal, making it expected rather than novel. The shift from a 6% ongoing royalty to a lump sum eliminates future recurring revenue in exchange for immediate, albeit immaterial, cash.
  • The NEX board transfer is a definitive negative catalyst. It signals that the company no longer meets active trading or operational requirements, severely restricts liquidity, and typically precedes voluntary delisting, bankruptcy, or complete liquidation.
  • The ~$531,000 proceeds are negligible for a pharmaceutical entity and will likely be consumed by administrative overhead, regulatory compliance, and potential undisclosed liabilities.
  • Overall impact is negative but fully aligned with the company's deteriorating operational and regulatory status.
AQS · Price
Company Overview
  • Aequus Pharmaceuticals operated in the specialty pharmaceutical sector, focusing on commercializing niche therapeutic products.
  • The flagship project, ZIMED PF, has been fully divested. The company no longer holds commercial assets or an active development pipeline.
  • Management appears to be executing a controlled wind-down rather than pursuing growth or new product development.
Read the original news release →